Adaptin Bio (APTN) Income from Continuing Operations (2023 - 2026)

Adaptin Bio (APTN) has 4 years of Income from Continuing Operations data on file, last reported at 1146096.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations fell 90.04% year-over-year to 1146096.0; the trailing twelve-month figure through Mar 2026 stood at 5710581.0 (down 69.77% YoY), and the FY2025 full-year result was 4082379.0, down 67.02% from the prior year.
• Income from Continuing Operations improved to 1146096.0 in Q1 2026, from 1368018.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 42938.0 in Q3 2023 to a low of 1675612.0 in Q3 2025.
• A 4-year average of 866017.09 and a median of 834279.0 in 2024 frame the typical range for Income from Continuing Operations.
• Across the five-year window, Income from Continuing Operations slumped 2479.42% in 2024 and sank 51.29% in 2025, its largest moves.
• Tracing APTN's Income from Continuing Operations over 4 years: stood at 69585.0 in 2023, then plunged by 1098.94% to 834279.0 in 2024, then plunged by 63.98% to 1368018.0 in 2025, then gained by 16.22% to 1146096.0 in 2026.
• Business Quant data shows APTN's Income from Continuing Operations at 1146096.0 in Q1 2026, 1368018.0 in Q4 2025, and 1675612.0 in Q3 2025.